Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

AVXL


Fundamental

Company: Anavex Life Sciences Corporation
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.54
Insider Own: 3.23%
Shs Outstand: 86.67M
Perf Week: -9.42%
Market Cap: 335.06M
Forward P/E: 2.95
EPS next Y: 1.27
Insider Trans: 0.00%
Shs Float: 86.46M
Perf Month: 18.30%
Enterprise Value: 232.48M
PEG: -
EPS next Q: -0.12
Inst Own: 36.62%
Short Float: 29.08%
Perf Quarter: -55.93%
Income: -46.38M
P/S: -
EPS this Y: 6.17%
Inst Trans: 0.01%
Short Ratio: 10.13
Perf Half Y: -60.77%
Sales: 0.00M
P/B: 3.43
EPS next Y Percentage: 350.66%
ROA: -38.75%
Short Interest: 25.14M
Perf YTD: -65.08%
Book/sh: 1.09
P/C: 3.27
EPS next 5Y: -
ROE: -43.11%
52W High: 14.44 -74.03%
Perf Year: -56.85%
Cash/sh: 1.15
P/FCF: -
EPS past 3/5Y: 4.47% -3.79%
ROIC: -48.88%
52W Low: 2.86 31.12%
Perf 3Y: -55.09%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 8.19%
Volatility M: 10.07%
Perf 5Y: -37.40%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -5.71%
Oper. Margin: -
ATR (14): 0.44
Perf 10Y: -50.72%
Dividend Ex-Date: -
Quick Ratio: 11.60
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 34.90
Recom: 1.67
Dividend Gr. 3/5Y: - -
Current Ratio: 11.60
EPS Q/Q: 16.50%
SMA20: -5.65%
Beta: 1.17
Target Price: 22.00
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: -36.19%
Rel Volume: 1.02
Prev Close: 3.67
Employees: 34
LT Debt/Eq: 0.00
Earnings: Nov 25 BMO
SMA200: -55.80%
Avg Volume: 2.48M
Price: 3.75
IPO: Aug 02, 2006
Option/Short: Yes / Yes
EPS/Sales Surpr.: 26.67% -
Trades:
Volume: 2,543,893
Change: 2.18%

Technical:


Latest News:

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference neutral
ANVS AVXL LGVN

Summary: Annovis Bio Inc. will participate in the H.C. Wainwright 26th Annual Global Investment Conference with a company presentation by Dr. Maccecchini discussing recent advancements and strategic direction, followed by a panel discussion on innovative non-amyloid approaches in Alzheimer’s disease.

Full article
2024-09-05T13:33:22Z